uric acid has been researched along with E coli Infections in 9 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Uric acid crystals were formed in vivo in the lumen of the gut in response to EPEC and STEC infections." | 1.43 | Biological Activities of Uric Acid in Infection Due to Enteropathogenic and Shiga-Toxigenic Escherichia coli. ( Broome, JE; Crane, JK; Lis, A, 2016) |
| " In Experiment 1, vitamin D3 was supplemented at a dosage of either 2,064 IU/kg (low level) or 4,128 IU/kg (high level) in drinking water provided ad libitum only from Days 1 through 5 after hatch." | 1.31 | The effect of vitamin D3 on resistance to stress-related infection in an experimental model of turkey osteomyelitis complex. ( Balog, JM; Huff, GR; Huff, WE; Rath, NC, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Balestracci, A | 2 |
| Meni Battaglia, L | 2 |
| Toledo, I | 2 |
| Beaudoin, L | 1 |
| Martin, SM | 2 |
| Grisolía, NA | 1 |
| Hogg, RJ | 1 |
| Crane, JK | 2 |
| Broome, JE | 2 |
| Lis, A | 1 |
| Lu, B | 1 |
| Nakamura, T | 1 |
| Inouye, K | 1 |
| Li, J | 1 |
| Tang, Y | 1 |
| Lundbäck, P | 1 |
| Valdes-Ferrer, SI | 1 |
| Olofsson, PS | 1 |
| Kalb, T | 1 |
| Roth, J | 1 |
| Zou, Y | 1 |
| Erlandsson-Harris, H | 1 |
| Yang, H | 1 |
| Ting, JP | 1 |
| Wang, H | 1 |
| Andersson, U | 1 |
| Antoine, DJ | 1 |
| Chavan, SS | 1 |
| Hotamisligil, GS | 1 |
| Tracey, KJ | 1 |
| Naeher, TM | 1 |
| Boedeker, EC | 1 |
| Friesen, A | 1 |
| Stern, J | 1 |
| Hofstetter, AG | 1 |
| Schilling, A | 1 |
| Huff, GR | 1 |
| Huff, WE | 1 |
| Balog, JM | 1 |
| Rath, NC | 1 |
| Gellman, AC | 1 |
| Malament, M | 1 |
| Notelovitz, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC): A Phase II Clinical Study[NCT01984892] | Phase 2 | 8 participants (Actual) | Interventional | 2013-11-30 | Terminated (stopped due to PI discretion, low enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patients who are alive on the date of closing follow-up, or 30 months after completing all study treatments, will be censored on that date (NCT01984892)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Participants With Stage 4 Cancer | 8 |
"Progression-free survival defined as the time in weeks from study entry until tumor progression defined using the Wolchok criteria or death. Patients who are alive and free from progression on the date of closing follow-up will be censored on that date.~In order to minimize the potential for misdiagnosis of pseudoprogression, related to early inflammation, tumor measurement for determination of progression will be made at the earliest at 26 weeks." (NCT01984892)
Timeframe: average 52 weeks
| Intervention | weeks (Number) |
|---|---|
| Participants With Stage 4 Cancer | 41 |
9 other studies available for uric acid and E coli Infections
| Article | Year |
|---|---|
Hyperuricemia: an unrecognized risk factor for kidney-related sequelae in children with hemolytic uremic syndrome.
Topics: Case-Control Studies; Child; Disease Progression; Escherichia coli Infections; Hemolytic-Uremic Synd | 2023 |
Rasburicase in hemolytic uremic syndrome related to Shiga toxin-producing Escherichia coli: a report of nine cases.
Topics: Child, Preschool; Dialysis; Escherichia coli Infections; Female; Hemolytic-Uremic Syndrome; Humans; | 2020 |
Biological Activities of Uric Acid in Infection Due to Enteropathogenic and Shiga-Toxigenic Escherichia coli.
Topics: Animals; Cell Line; Colforsin; Enterohemorrhagic Escherichia coli; Escherichia coli Infections; Gast | 2016 |
Novel role of PKR in inflammasome activation and HMGB1 release.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphate; Animals; Antigens, Bacterial; Apoptosi | 2012 |
Role of host xanthine oxidase in infection due to enteropathogenic and Shiga-toxigenic Escherichia coli.
Topics: Animals; Bodily Secretions; Cell Line; Disease Models, Animal; Enteropathogenic Escherichia coli; Es | 2013 |
[Nephrolithiasis--correlation of calculus type and pathogen spectrum. Calculus analysis and microbiologic diagnosis in 173 surgically treated patients].
Topics: Bacteriological Techniques; Calcium Oxalate; Escherichia coli Infections; Female; Humans; Kidney Cal | 1984 |
The effect of vitamin D3 on resistance to stress-related infection in an experimental model of turkey osteomyelitis complex.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Blood Glucose; Bod | 2000 |
Partial nephrectomy in renal calculus disease.
Topics: Adult; Aged; Dilatation; Escherichia coli Infections; Follow-Up Studies; Humans; Kidney; Kidney Calc | 1973 |
The pregnant Natal Indian diabetic.
Topics: Adolescent; Adrenal Glands; Adult; Blood Glucose; Body Height; Body Weight; Cholesterol; Escherichia | 1969 |